Sanofi SA, of Paris, said its Genzyme unit disclosed the publication of results from the phase III ENCORE study exploring Cerdelga (eliglustat) as a maintenance therapy suitable for adult patients who had reached pre-specific treatment goals on enzyme replacement therapy (ERT) in the online issue of The Lancet.